Tuberculosis: The Power of Innovation and Partnership

Mel Spigelman, M.D.
Global Alliance for TB Drug Development
Washington, DC - March 19, 2012
TB Alliance Vision

Success will require novel drug combinations

Current Treatment: 6-30 Months

New Treatments in Development: 2-4 Months

Our Vision: 7-10 Days
TB Drug/Regimen

Discovery and Development Process

Identification of New Drug Candidates

Selection of Potential New Regimens

Drug Candidate Pool

Discovery

Compound 1

Compound 2

Compound 3

Compound 4

Compound 5

Single Compound Preclinical Development → Phase I → EBA

Phase II → Phase III

Regimen A

Regimen B

Regimen C

Regimen Identification

CURE All: A briefing on promising new TB drugs research
Launch of the Critical Path to TB Drug Regimens (CPTR)
CPTTR Initiative
Tackling Challenges to TB Drug Development

Critical Path to TB Drug Regimens

CPTR Regulatory Science Consortium
Led by the Critical Path Institute

CPTR Drugs Coalition
Led by the TB Alliance

CPTR Research Resources
Led by the Bill and Melinda Gates Foundation

Focus

- Data standards & integration
- Biomarkers and endpoints as disease response assays
- Animal models
- Pharmacology
- Disease progression models

- Drug combination testing and development

- Clinical trials infrastructure
- Resource mobilization
- Regulatory harmonization
- Access and appropriate use
NC-002 – A New Pathway to Treating TB

The Promise of NC-002

- Oral, once daily regimen consisting of PA-824 + moxifloxacin + pyrazinamide (PaMZ)
- 8-week trial at 8 sites
- Promising attributes of NC-002
  - First-ever testing of a regimen in both DS- and MDR-TB patients at the same time
  - Potential for major impact
    - shorten MDR-TB therapy by 80%
    - decrease cost of treating MDR-TB by 90%
    - compatible with simultaneous use of anti-retrovirals (ARVs)
    - dramatically ease delivery and distribution logistics
- Pace and scope of new TB regimen trials to accelerate in 2012-13
A world without TB...